EUVIMEDEUVIMED entdecken
Open Access · CC BY 3.0

Absence of Hepatitis B Resistance Mutants before Introduction of Oral Antiviral Therapy

Martin Moehlen, Maria De Medina, Mary Hill, Lennox Jeffers, Eugene R Schiff, Paul Martin

ISRN Hepatology · 2013

DOI: 10.1155/2013/130384 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ISRN Hepatology, 2013. Verfasst von Martin Moehlen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Section of Gastroenterology & Hepatology, Department of Internal Medicine, School of Medicine, Tulane University, 1430 Tulane Avenue, SL-35, New Orle…. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The aim of this study was to assess whether hepatitis B virus drug resistant mutations antedated the widespread use of nucleos(t)ide analogues in treatment naïve patients. A number of reports have suggested that drug resistant mutants can be detected in apparently treatment naïve patients. Study . Fifty deidentified serum samples collected from 1986 to 1992 from patients with replicative chronic HBV infection at the University of Miami were genotyped and tested for resistance mutations using a line probe assay InnoLiPA HBV DR v2/v3. Serum HBV DNA was measured. All patients had documented chronic HBV infection with a detectable viral load, HBeAg seropositivity, and absence of HIV infection.

Results

Of the 50 individuals included, 86% were male, mean age was 40 ± 12 years, and mostly genotype A. The mean HBV DNA was 126 pg/mL (range 6.4 to 557.0). No mutations were identified.

Conclusions

The absence of drug induced mutations in these sera collected several years prior to the introduction of oral antiviral therapy suggests that these mutations do not occur in treatment naïve populations. Detection of drug resistance in an apparently treatment naïve subject suggests either unrecognized prior antiviral therapy or infection by an inoculum from a treatment experienced patient.

Autor:innen und Institutionen

  • Section of Gastroenterology & Hepatology, Department of Internal Medicine, School of Medicine, Tulane University, 1430 Tulane Avenue, SL-35, New Orleans, LA 70112, USA.
  • Center for Liver Diseases, University of Miami, School of Medicine, 1500 NW 12th Avenue, Suite 1101, Miami, FL 33136, USA.

Zitieren

APA

Moehlen, M., De Medina, M., Hill, M., Jeffers, L., Schiff, E. R., & Martin, P. (2013). Absence of Hepatitis B Resistance Mutants before Introduction of Oral Antiviral Therapy. ISRN Hepatology. https://doi.org/10.1155/2013/130384

Vancouver

Moehlen M, De Medina M, Hill M, Jeffers L, Schiff ER, Martin P. Absence of Hepatitis B Resistance Mutants before Introduction of Oral Antiviral Therapy. ISRN Hepatology. 2013. doi:10.1155/2013/130384

BibTeX
@article{Moehlen2013,
  author = {Moehlen, Martin and De Medina, Maria and Hill, Mary and Jeffers, Lennox and Schiff, Eugene R and Martin, Paul},
  title = {Absence of Hepatitis B Resistance Mutants before Introduction of Oral Antiviral Therapy},
  journal = {ISRN Hepatology},
  year = {2013},
  doi = {10.1155/2013/130384}
}
Kostenlos starten →